Details of the Drug

General Information of Drug (ID: DMQYUWG)

Drug Name
Toremifene
Synonyms
Acapodene; Estrimex; Farestone; Toremifeno; Toremifenum; Toremifene Base; Toremifeno [Spanish]; Toremifenum [Latin]; GTx 006; Acapodene (TN); FC-1157a; Fareston (TN); GTx-006; Toremifene (INN); Toremifene [INN:BAN]; Z-Toremifene; GTX-006 (Acapodene); Toremifene Citrate (1:1); {2-[4-(4-Chloro-1,2-diphenyl-but-1-enyl)-phenoxy]-ethyl}-dimethyl-amine; (Z)-2-(4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; 2-(p-[(Z)-4-chloro-1,2-diphenyl-1-butenyl]-phenoxy)-N,N-dimethyl-ethylamine citrate(1:1); 2-(para-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine (IUPAC); 2-({4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenyl}oxy)-N,N-dimethylethanamine; 2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [1], [2]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 406
Topological Polar Surface Area (xlogp) 7.2
Rotatable Bond Count (rotbonds) 9
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability
99% of drug becomes completely available to its intended biological destination(s) [4]
Elimination
0.1% of drug is excreted from urine in the unchanged form [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 8.20253 micromolar/kg/day [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.38 mg/mL [3]
Chemical Identifiers
Formula
C26H28ClNO
IUPAC Name
2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
Canonical SMILES
CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCl)\\C2=CC=CC=C2)/C3=CC=CC=C3
InChI
InChI=1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25-
InChIKey
XFCLJVABOIYOMF-QPLCGJKRSA-N
Cross-matching ID
PubChem CID
3005573
ChEBI ID
CHEBI:9635
CAS Number
89778-26-7
DrugBank ID
DB00539
TTD ID
D04VFJ
VARIDT ID
DR01170
INTEDE ID
DR1623
ACDINA ID
D00691

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Estrogen receptor (ESR) TTZAYWL ESR1_HUMAN Modulator [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [8]
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Substrate [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Breast cancer
ICD Disease Classification 2C60-2C65
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
P-glycoprotein 1 (ABCB1) DTP P-GP 7.23E-01 -8.20E-02 -3.22E-01
Cytochrome P450 1A1 (CYP1A1) DME CYP1A1 5.01E-01 -1.01E-02 -6.05E-02
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 9.85E-01 2.24E-02 7.33E-02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Toremifene
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Toremifene and Eribulin. Breast cancer [2C60-2C6Y] [42]
Lapatinib DM3BH1Y Major Increased risk of prolong QT interval by the combination of Toremifene and Lapatinib. Breast cancer [2C60-2C6Y] [42]
Tucatinib DMBESUA Major Decreased metabolism of Toremifene caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [43]
Bosutinib DMTI8YE Major Increased risk of prolong QT interval by the combination of Toremifene and Bosutinib. Breast cancer [2C60-2C6Y] [42]
Coadministration of a Drug Treating the Disease Different from Toremifene (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Metreleptin DM1NOEK Moderate Increased metabolism of Toremifene caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [44]
Pioglitazone DMKJ485 Moderate Increased metabolism of Toremifene caused by Pioglitazone mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [45]
Nateglinide DMLK2QH Moderate Decreased metabolism of Toremifene caused by Nateglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [46]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Toremifene and Ivosidenib. Acute myeloid leukaemia [2A60] [42]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Toremifene and Midostaurin. Acute myeloid leukaemia [2A60] [42]
Idarubicin DMM0XGL Major Increased risk of prolong QT interval by the combination of Toremifene and Idarubicin. Acute myeloid leukaemia [2A60] [42]
Daunorubicin DMQUSBT Major Increased risk of prolong QT interval by the combination of Toremifene and Daunorubicin. Acute myeloid leukaemia [2A60] [42]
Arn-509 DMT81LZ Major Increased metabolism of Toremifene caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [44]
Gilteritinib DMWQ4MZ Major Increased risk of prolong QT interval by the combination of Toremifene and Gilteritinib. Acute myeloid leukaemia [2A60] [42]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Toremifene and Oliceridine. Acute pain [MG31] [42]
Mitotane DMU1GX0 Major Increased metabolism of Toremifene caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [44]
Galantamine DMEO794 Moderate Increased risk of ventricular arrhythmias by the combination of Toremifene and Galantamine. Alzheimer disease [8A20] [42]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Toremifene and Rivastigmine. Alzheimer disease [8A20] [42]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Toremifene and Donepezil. Alzheimer disease [8A20] [42]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Toremifene and Metronidazole. Amoebiasis [1A36] [47]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Toremifene and Bepridil. Angina pectoris [BA40] [42]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Toremifene and Dronedarone. Angina pectoris [BA40] [42]
Nifedipine DMSVOZT Moderate Decreased metabolism of Toremifene caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [43]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Toremifene and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [42]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Toremifene caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [47]
Hydroxyzine DMF8Y74 Major Increased risk of prolong QT interval by the combination of Toremifene and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [42]
Cilostazol DMZMSCT Major Increased risk of prolong QT interval by the combination of Toremifene and Cilostazol. Arterial occlusive disease [BD40] [42]
Voriconazole DMAOL2S Major Decreased metabolism of Toremifene caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [43]
Posaconazole DMUL5EW Major Increased risk of prolong QT interval by the combination of Toremifene and Posaconazole. Aspergillosis [1F20] [42]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Toremifene and Levalbuterol. Asthma [CA23] [48]
Terbutaline DMD4381 Major Increased risk of prolong QT interval by the combination of Toremifene and Terbutaline. Asthma [CA23] [49]
Zafirlukast DMHNQOG Moderate Decreased metabolism of Toremifene caused by Zafirlukast mediated inhibition of CYP450 enzyme. Asthma [CA23] [43]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Toremifene and Pirbuterol. Asthma [CA23] [49]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Toremifene and Salbutamol. Asthma [CA23] [50]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Toremifene and Formoterol. Asthma [CA23] [49]
Lisdexamfetamine DM6W8V5 Major Increased risk of prolong QT interval by the combination of Toremifene and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [42]
Desipramine DMT2FDC Major Increased risk of prolong QT interval by the combination of Toremifene and Desipramine. Attention deficit hyperactivity disorder [6A05] [42]
Ofloxacin DM0VQN3 Major Increased risk of prolong QT interval by the combination of Toremifene and Ofloxacin. Bacterial infection [1A00-1C4Z] [42]
Oritavancin DM28D05 Moderate Increased metabolism of Toremifene caused by Oritavancin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [44]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Toremifene caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [51]
Clarithromycin DM4M1SG Major Decreased metabolism of Toremifene caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [43]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Toremifene and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [42]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Toremifene and Sparfloxacin. Bacterial infection [1A00-1C4Z] [52]
Gemifloxacin DMHT34O Major Increased risk of prolong QT interval by the combination of Toremifene and Gemifloxacin. Bacterial infection [1A00-1C4Z] [42]
Norfloxacin DMIZ6W2 Major Increased risk of prolong QT interval by the combination of Toremifene and Norfloxacin. Bacterial infection [1A00-1C4Z] [42]
Troleandomycin DMUZNIG Major Decreased metabolism of Toremifene caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [43]
Lomefloxacin DMVRH9C Major Increased risk of prolong QT interval by the combination of Toremifene and Lomefloxacin. Bacterial infection [1A00-1C4Z] [42]
Telithromycin DMZ4P3A Major Decreased metabolism of Toremifene caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [43]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Toremifene and Retigabine. Behcet disease [4A62] [42]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Toremifene caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [44]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Toremifene and Loperamide. Bowel habit change [ME05] [53]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Toremifene and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [42]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Toremifene and Olodaterol. Chronic obstructive pulmonary disease [CA22] [49]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Toremifene and Vilanterol. Chronic obstructive pulmonary disease [CA22] [48]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Toremifene and Salmeterol. Chronic obstructive pulmonary disease [CA22] [49]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Toremifene and Indacaterol. Chronic obstructive pulmonary disease [CA22] [49]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Toremifene and Arformoterol. Chronic obstructive pulmonary disease [CA22] [49]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Toremifene caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [44]
Anisindione DM2C48U Moderate Decreased metabolism of Toremifene caused by Anisindione mediated inhibition of CYP450 enzyme. Coagulation defect [3B10] [47]
Isoproterenol DMK7MEY Major Increased risk of prolong QT interval by the combination of Toremifene and Isoproterenol. Conduction disorder [BC63] [49]
Halothane DM80OZ5 Major Increased risk of prolong QT interval by the combination of Toremifene and Halothane. Corneal disease [9A76-9A78] [42]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Toremifene and Propofol. Corneal disease [9A76-9A78] [54]
Sevoflurane DMC9O43 Major Increased risk of prolong QT interval by the combination of Toremifene and Sevoflurane. Corneal disease [9A76-9A78] [42]
Probucol DMVZQ2M Major Increased risk of prolong QT interval by the combination of Toremifene and Probucol. Coronary atherosclerosis [BA80] [42]
Clofazimine DMEBOFW Major Increased risk of prolong QT interval by the combination of Toremifene and Clofazimine. Crohn disease [DD70] [42]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Toremifene and Mifepristone. Cushing syndrome [5A70] [42]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Toremifene and Pasireotide. Cushing syndrome [5A70] [42]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Toremifene and Osilodrostat. Cushing syndrome [5A70] [42]
Lumacaftor DMCLWDJ Major Increased metabolism of Toremifene caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [44]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Toremifene caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [43]
MK-8228 DMOB58Q Moderate Decreased metabolism of Toremifene caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [43]
Aprepitant DM053KT Moderate Decreased metabolism of Toremifene caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [43]
Sertraline DM0FB1J Major Increased risk of prolong QT interval by the combination of Toremifene and Sertraline. Depression [6A70-6A7Z] [42]
Trimipramine DM1SC8M Major Increased risk of prolong QT interval by the combination of Toremifene and Trimipramine. Depression [6A70-6A7Z] [42]
Nortriptyline DM4KDYJ Major Increased risk of prolong QT interval by the combination of Toremifene and Nortriptyline. Depression [6A70-6A7Z] [42]
Nefazodone DM4ZS8M Major Decreased metabolism of Toremifene caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [43]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Toremifene and Escitalopram. Depression [6A70-6A7Z] [42]
Clomipramine DMINRKW Major Increased risk of prolong QT interval by the combination of Toremifene and Clomipramine. Depression [6A70-6A7Z] [42]
Trazodone DMK1GBJ Major Increased risk of prolong QT interval by the combination of Toremifene and Trazodone. Depression [6A70-6A7Z] [42]
Amoxapine DMKITQE Major Increased risk of prolong QT interval by the combination of Toremifene and Amoxapine. Depression [6A70-6A7Z] [42]
Doxepin DMPI98T Major Increased risk of prolong QT interval by the combination of Toremifene and Doxepin. Depression [6A70-6A7Z] [42]
Maprotiline DMPWB7T Major Increased risk of prolong QT interval by the combination of Toremifene and Maprotiline. Depression [6A70-6A7Z] [42]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Toremifene and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [42]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Toremifene and Deutetrabenazine. Dystonic disorder [8A02] [42]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Toremifene and Ingrezza. Dystonic disorder [8A02] [42]
Primidone DM0WX6I Major Increased metabolism of Toremifene caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [44]
Felbamate DM1V5ZS Moderate Increased metabolism of Toremifene caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [44]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Toremifene caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [44]
Cenobamate DMGOVHA Moderate Increased metabolism of Toremifene caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [44]
Stiripentol DMMSDOY Moderate Decreased metabolism of Toremifene caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [43]
Fosphenytoin DMOX3LB Major Increased metabolism of Toremifene caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [44]
Rufinamide DMWE60C Moderate Increased metabolism of Toremifene caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [44]
Phenobarbital DMXZOCG Major Increased metabolism of Toremifene caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [44]
Carbamazepine DMZOLBI Major Increased metabolism of Toremifene caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [44]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Toremifene caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [44]
Tazemetostat DMWP1BH Moderate Increased metabolism of Toremifene caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [44]
Solifenacin DMG592Q Major Increased risk of prolong QT interval by the combination of Toremifene and Solifenacin. Functional bladder disorder [GC50] [42]
Itraconazole DMCR1MV Major Decreased metabolism of Toremifene caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [43]
Pentamidine DMHZJCG Major Increased risk of prolong QT interval by the combination of Toremifene and Pentamidine. Fungal infection [1F29-1F2F] [42]
Miconazole DMPMYE8 Moderate Decreased metabolism of Toremifene caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [43]
Ketoconazole DMPZI3Q Major Decreased metabolism of Toremifene caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [43]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Toremifene and Cisapride. Gastro-oesophageal reflux disease [DA22] [42]
Sunitinib DMCBJSR Major Increased risk of prolong QT interval by the combination of Toremifene and Sunitinib. Gastrointestinal stromal tumour [2B5B] [42]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Toremifene caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [44]
Boceprevir DMBSHMF Major Decreased metabolism of Toremifene caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [43]
Telaprevir DMMRV29 Major Decreased metabolism of Toremifene caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [43]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Toremifene caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [43]
Rifampin DMA8J1G Major Increased metabolism of Toremifene caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [44]
Delavirdine DM3NF5G Major Decreased metabolism of Toremifene caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [43]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Toremifene caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [43]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Toremifene and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [42]
Cobicistat DM6L4H2 Major Decreased metabolism of Toremifene caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [43]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Toremifene and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [42]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Toremifene and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [55]
Etravirine DMGV8QU Moderate Increased metabolism of Toremifene caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [44]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Toremifene and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [42]
Amprenavir DMLMXE0 Major Decreased metabolism of Toremifene caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [43]
Darunavir DMN3GCH Moderate Decreased metabolism of Toremifene caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [43]
Atazanavir DMSYRBX Major Decreased metabolism of Toremifene caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [43]
Fluvastatin DM4MDJY Moderate Decreased metabolism of Toremifene caused by Fluvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [47]
Verapamil DMA7PEW Moderate Decreased metabolism of Toremifene caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [43]
Conivaptan DM1V329 Major Decreased metabolism of Toremifene caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [43]
Lesinurad DMUR64T Moderate Decreased metabolism of Toremifene caused by Lesinurad mediated inhibition of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [56]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Toremifene caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [43]
Amobarbital DM0GQ8N Moderate Increased metabolism of Toremifene caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [44]
Polyethylene glycol DM4I1JP Major Increased risk of ventricular arrhythmias by the combination of Toremifene and Polyethylene glycol. Irritable bowel syndrome [DD91] [57]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Toremifene and Phenolphthalein. Irritable bowel syndrome [DD91] [42]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Toremifene and Crizotinib. Lung cancer [2C25] [42]
Brigatinib DM7W94S Moderate Increased metabolism of Toremifene caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [44]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Toremifene and Ceritinib. Lung cancer [2C25] [42]
PF-06463922 DMKM7EW Moderate Increased metabolism of Toremifene caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [44]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Toremifene and Osimertinib. Lung cancer [2C25] [42]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Toremifene and Selpercatinib. Lung cancer [2C25] [42]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Toremifene and Lumefantrine. Malaria [1F40-1F45] [47]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Toremifene and Halofantrine. Malaria [1F40-1F45] [58]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Toremifene and Chloroquine. Malaria [1F40-1F45] [42]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Toremifene and Hydroxychloroquine. Malaria [1F40-1F45] [42]
Primaquine DMWQ16I Major Increased risk of prolong QT interval by the combination of Toremifene and Primaquine. Malaria [1F40-1F45] [42]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Toremifene and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [42]
Idelalisib DM602WT Major Decreased metabolism of Toremifene caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [43]
IPI-145 DMWA24P Moderate Decreased metabolism of Toremifene caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [43]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Toremifene and Arsenic trioxide. Mature B-cell lymphoma [2A85] [59]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Toremifene and Vemurafenib. Melanoma [2C30] [42]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Toremifene and LGX818. Melanoma [2C30] [42]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Toremifene caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [60]
Danazol DML8KTN Moderate Decreased metabolism of Toremifene caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [43]
Exjade DMHPRWG Moderate Increased metabolism of Toremifene caused by Exjade mediated induction of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [44]
Carfilzomib DM48K0X Major Additive thrombogenic effects by the combination of Toremifene and Carfilzomib. Multiple myeloma [2A83] [47]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Toremifene and Panobinostat. Multiple myeloma [2A83] [42]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Toremifene and Siponimod. Multiple sclerosis [8A40] [47]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Toremifene and Fingolimod. Multiple sclerosis [8A40] [42]
Ozanimod DMT6AM2 Major Increased risk of prolong QT interval by the combination of Toremifene and Ozanimod. Multiple sclerosis [8A40] [42]
Rifabutin DM1YBHK Major Increased metabolism of Toremifene caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [44]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Toremifene and Romidepsin. Mycosis fungoides [2B01] [42]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Toremifene caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [43]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Toremifene and Nilotinib. Myeloproliferative neoplasm [2A20] [42]
Imatinib DM7RJXL Moderate Decreased metabolism of Toremifene caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [43]
Dasatinib DMJV2EK Major Increased risk of prolong QT interval by the combination of Toremifene and Dasatinib. Myeloproliferative neoplasm [2A20] [42]
Modafinil DMYILBE Moderate Increased metabolism of Toremifene caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [44]
Promethazine DM6I5GR Major Increased risk of prolong QT interval by the combination of Toremifene and Promethazine. Nausea/vomiting [MD90] [42]
Granisetron DMIUW25 Major Increased risk of prolong QT interval by the combination of Toremifene and Granisetron. Nausea/vomiting [MD90] [42]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Toremifene and Dolasetron. Nausea/vomiting [MD90] [42]
Ondansetron DMOTQ1I Major Increased risk of prolong QT interval by the combination of Toremifene and Ondansetron. Nausea/vomiting [MD90] [42]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Toremifene and Entrectinib. Non-small cell lung cancer [2C25] [42]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Toremifene and Levomethadyl Acetate. Opioid use disorder [6C43] [60]
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Toremifene and Lofexidine. Opioid use disorder [6C43] [42]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Toremifene and Rucaparib. Ovarian cancer [2C73] [42]
Dextropropoxyphene DM23HCX Major Increased risk of prolong QT interval by the combination of Toremifene and Dextropropoxyphene. Pain [MG30-MG3Z] [42]
Buprenorphine DMPRI8G Major Increased risk of prolong QT interval by the combination of Toremifene and Buprenorphine. Pain [MG30-MG3Z] [42]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Toremifene and Triclabendazole. Parasitic worm infestation [1F90] [42]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Toremifene and Pimavanserin. Parkinsonism [8A00] [42]
Apomorphine DMX38HQ Major Increased risk of prolong QT interval by the combination of Toremifene and Apomorphine. Parkinsonism [8A00] [42]
Abametapir DM2RX0I Moderate Decreased metabolism of Toremifene caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [61]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Toremifene and Famotidine. Peptic ulcer [DA61] [47]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Toremifene and Macimorelin. Pituitary gland disorder [5A60-5A61] [62]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Toremifene and Lefamulin. Pneumonia [CA40] [63]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Toremifene caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [43]
Ritodrine DM4V6RL Major Increased risk of prolong QT interval by the combination of Toremifene and Ritodrine. Preterm labour/delivery [JB00] [49]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Toremifene and Degarelix. Prostate cancer [2C82] [42]
ABIRATERONE DM8V75C Major Increased risk of prolong QT interval by the combination of Toremifene and ABIRATERONE. Prostate cancer [2C82] [42]
Nilutamide DMFN07X Major Increased risk of prolong QT interval by the combination of Toremifene and Nilutamide. Prostate cancer [2C82] [42]
Enzalutamide DMGL19D Major Increased metabolism of Toremifene caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [44]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Toremifene and Relugolix. Prostate cancer [2C82] [42]
Bicalutamide DMZMSPF Major Increased risk of prolong QT interval by the combination of Toremifene and Bicalutamide. Prostate cancer [2C82] [42]
Levomepromazine DMIKFEL Major Increased risk of prolong QT interval by the combination of Toremifene and Levomepromazine. Psychotic disorder [6A20-6A25] [42]
Fluphenazine DMIT8LX Major Increased risk of prolong QT interval by the combination of Toremifene and Fluphenazine. Psychotic disorder [6A20-6A25] [42]
Bosentan DMIOGBU Moderate Increased metabolism of Toremifene caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [44]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Toremifene and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [64]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Toremifene and Gatifloxacin. Respiratory infection [CA07-CA4Z] [42]
Dexamethasone DMMWZET Major Increased metabolism of Toremifene caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [44]
Nafcillin DMN9RPO Moderate Increased metabolism of Toremifene caused by Nafcillin mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [44]
Quetiapine DM1N62C Major Increased risk of prolong QT interval by the combination of Toremifene and Quetiapine. Schizophrenia [6A20] [42]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Toremifene and Mesoridazine. Schizophrenia [6A20] [42]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Toremifene and Thioridazine. Schizophrenia [6A20] [42]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Toremifene and Aripiprazole. Schizophrenia [6A20] [47]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Toremifene and Iloperidone. Schizophrenia [6A20] [42]
Paliperidone DM7NPJS Major Increased risk of prolong QT interval by the combination of Toremifene and Paliperidone. Schizophrenia [6A20] [42]
Perphenazine DMA4MRX Major Increased risk of prolong QT interval by the combination of Toremifene and Perphenazine. Schizophrenia [6A20] [42]
Trifluoperazine DMKBYWI Major Increased risk of prolong QT interval by the combination of Toremifene and Trifluoperazine. Schizophrenia [6A20] [42]
Risperidone DMN6DXL Major Increased risk of prolong QT interval by the combination of Toremifene and Risperidone. Schizophrenia [6A20] [42]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Toremifene and Amisulpride. Schizophrenia [6A20] [42]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Toremifene and Asenapine. Schizophrenia [6A20] [42]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Toremifene and Pimozide. Schizophrenia [6A20] [60]
Vardenafil DMTBGW8 Major Increased risk of prolong QT interval by the combination of Toremifene and Vardenafil. Sexual dysfunction [HA00-HA01] [42]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Toremifene caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [43]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Toremifene caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [47]
Larotrectinib DM26CQR Moderate Decreased metabolism of Toremifene caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [43]
Armodafinil DMGB035 Moderate Increased metabolism of Toremifene caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [44]
LEE011 DMMX75K Major Decreased metabolism of Toremifene caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [42]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Toremifene and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [65]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Toremifene and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [42]
Doxorubicin DMVP5YE Major Increased risk of prolong QT interval by the combination of Toremifene and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [42]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Toremifene and Pitolisant. Somnolence [MG42] [42]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Toremifene and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [42]
Warfarin DMJYCVW Moderate Decreased metabolism of Toremifene caused by Warfarin mediated inhibition of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [47]
Adenosine DMM2NSK Major Increased risk of ventricular arrhythmias by the combination of Toremifene and Adenosine. Supraventricular tachyarrhythmia [BC81] [66]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Toremifene caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [67]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Toremifene and Lenvatinib. Thyroid cancer [2D10] [42]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Toremifene and Cabozantinib. Thyroid cancer [2D10] [42]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Toremifene and Papaverine. Tonus and reflex abnormality [MB47] [68]
Tizanidine DMR2IQ4 Major Increased risk of prolong QT interval by the combination of Toremifene and Tizanidine. Tonus and reflex abnormality [MB47] [42]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Toremifene and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [64]
Tacrolimus DMZ7XNQ Major Increased risk of prolong QT interval by the combination of Toremifene and Tacrolimus. Transplant rejection [NE84] [42]
Elagolix DMB2C0E Moderate Increased metabolism of Toremifene caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [44]
Astemizole DM2HN6Q Major Increased risk of prolong QT interval by the combination of Toremifene and Astemizole. Vasomotor/allergic rhinitis [CA08] [42]
Trimeprazine DMEMV9D Major Increased risk of prolong QT interval by the combination of Toremifene and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [42]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Toremifene and Procainamide. Ventricular tachyarrhythmia [BC71] [42]
Propafenone DMPIBJK Major Increased risk of prolong QT interval by the combination of Toremifene and Propafenone. Ventricular tachyarrhythmia [BC71] [42]
Flecainide DMSQDLE Major Increased risk of prolong QT interval by the combination of Toremifene and Flecainide. Ventricular tachyarrhythmia [BC71] [42]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Toremifene and Amiodarone. Ventricular tachyarrhythmia [BC71] [42]
⏷ Show the Full List of 225 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Toremifene 60 mg tablet 60 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4325).
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Effect of selective estrogen receptor modulators on cell proliferation and estrogen receptor activities in normal human prostate stromal and epithe... Prostate Cancer Prostatic Dis. 2009;12(4):375-81.
7 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
8 Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms. Xenobiotica. 2011 Oct;41(10):851-62.
9 Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem Pharmacol. 1994 May 18;47(10):1883-95.
10 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
11 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
12 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
13 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
14 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
15 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
16 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
17 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
18 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
19 Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
20 Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
21 Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
22 Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7.
23 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
24 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
25 A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
26 Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
27 Disruption of endogenous regulator homeostasis underlies the mechanism of rat CYP1A1 mRNA induction by metyrapone. Biochem J. 1998 Apr 1;331 ( Pt 1):273-81.
28 Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
29 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
30 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
31 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
32 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
33 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
34 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
35 Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause. Recent Pat Cardiovasc Drug Discov. 2008 Nov;3(3):165-86.
36 Reprint of Are all estrogens the same Maturitas. 2008 Sep-Oct;61(1-2):195-201.
37 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
38 17alpha-Ethinylestradiol hinders nucleotide excision repair in zebrafish liver cells. Aquat Toxicol. 2009 Dec 13;95(4):273-8.
39 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
40 Clinical pipeline report, company report or official report of Shionogi (2011).
41 Short-term effects of environmentally relevant concentrations of EDC mixtures on Mytilus galloprovincialis digestive gland. Aquat Toxicol. 2008 May 30;87(4):272-9.
42 Canadian Pharmacists Association.
43 Product Information. Fareston (toremifene). Schering Laboratories, Kenilworth, NJ.
44 Berthou F, Dreano Y, Belloc C, Kangas L, Gautier JC, Beaune P "Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes." Biochem Pharmacol 47 (1994): 1883-95. [PMID: 8204106]
45 Product Information. Actos (pioglitazone) Takeda Pharmaceuticals America, Lincolnshire, IL.
46 Product Information. Starlix (nateglinide) Novartis Pharmaceuticals, East Hanover, NJ.
47 Cerner Multum, Inc. "Australian Product Information.".
48 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
49 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
50 Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6. [PMID: 3168573]
51 Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
52 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
53 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
54 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
55 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
56 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
57 Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
58 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
59 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
60 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
61 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
62 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
63 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
64 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
65 Product Information. Vandetanib (vandetanib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
66 Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994): 1814-7. [PMID: 7838793]
67 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
68 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]